Can a gut antibiotic ease Chemo's stomach woes in breast cancer?
NCT ID NCT04249622
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 30 times
Summary
This phase II trial tested whether the antibiotic rifaximin could reduce stomach-related side effects like diarrhea and pain in patients with early-stage HER2-positive breast cancer receiving pertuzumab-based chemotherapy. The study planned to enroll 20 patients but was terminated early. The goal was to see if rifaximin could help patients complete their cancer therapy without dose delays or reductions due to gastrointestinal issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rifaximin (Xifaxan)
What this could lead to
If it worked, rifaximin could help manage diarrhea and stomach pain caused by pertuzumab-based chemotherapy, allowing patients to stay on their cancer treatment without delays.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. It only tested one specific side effect in one cancer type, and the drug may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.